Aspirin Continuation or Discontinuation in Conservative Treatment for Chronic Subdural Hematoma

ConditionChronic Subdural Hematoma

Trial statusRecruiting

Trial phaseNot applicable

Trial typeInterventional

Biological sexAll

Age18+

SponsorTao Liu

About this trial

This clinical study aims to learn about the efficacy and safety of aspirin continuation or discontinuation in conservative treatment for chronic subdural hematoma. All participants received standard conservative treatment for chronic subdural hematoma, with a randomized intervention to either continue or discontinue aspirin administration. By participating in this study, participants can receive additional scientific guidance on aspirin medication management beyond routine conservative treatment, thereby optimizing individualized therapy.

Eligibility criteria

Qualifiers

Age ≥18 years, male or female;

Confirmed diagnosis of chronic subdural hematoma (cSDH) by cranial CT and/or MRI;

Intended for conservative management (i.e., no surgical evacuation indication at enrollment);

Regular aspirin use at enrollment;

Disqualifiers

Patients requiring emergency surgery to remove hematoma at enrollment;

Concurrent use of other anticoagulants or antiplatelet agents that cannot be discontinued according to the study protocol;

cSDH secondary to other diseases or conditions (e.g., excessive drainage from ventriculoperitoneal shunts, intracranial tumors);

Active bleeding events or major cardiac events (e.g., acute myocardial infarction, unstable angina, or revascularization surgery) within 30 days prior to enrollment;

Trial design

Treatments tested in this trial

Aspirin Continuation
Aspirin Discontinuation

Treatment groups

143 Participants

are divided into 2 treatment groups

Sponsors and collaborators

Tao Liu

Lead sponsor

The George Institute

Sponsor institution

Tianjin Medical University General Hospital

Collaborator

Xuanwu Hospital, Beijing

Collaborator

Source ClinicalTrials.gov